Document:

Form of Note issued under the Fourth Amended & Restated Note

 Exhibit 10.15 

NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY
STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR ASSIGNED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SAID ACT AND STATE SECURITIES LAWS OR SOME OTHER EXEMPTION FROM THE REGISTRATION
REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 

THIS NOTE IS SUBJECT TO A FOURTH AMENDED AND RESTATED SUBORDINATION AGREEMENT DATED OCTOBER 1, 2010 BETWEEN THE COMPANY AND HERCULES TECHNOLOGY GROWTH
CAPITAL, INC., A COPY OF WHICH MAY BE OBTAINED UPON WRITTEN REQUEST FROM THE COMPANY. 
 AEGERION PHARMACEUTICALS, INC.

 SENIOR SUBORDINATED CONVERTIBLE PROMISSORY NOTE 

 

			
	$[            ]	  	October 1, 2010

 FOR VALUE
RECEIVED, Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby promises to pay to the order of [            ] (or its successors or
assigns, the “Holder”), the principal amount of [                    ]
($[            ]), plus interest in arrears from and including the date hereof on the principal balance from time to time outstanding, accruing daily, at a rate per annum equal to
eight percent (8%) for the time period beginning on the date hereof and ending on the Maturity Date. This Senior Subordinated Convertible Promissory Note (this “Note”) may not be prepaid in whole or in part without the
written consent of the Required Purchasers. For avoidance of doubt, no interest payments shall be due prior to the earlier of: (i) Maturity as set forth in Section 2 of this Note, (ii) acceleration due to an Event of Default (defined
below), or (iii) conversion of the Note as set forth in Sections 3, 4 and 5 of this Note, as the case may be. Interest shall be calculated on the basis of actual number of days elapsed over a year of 365 days. Notwithstanding any other
provision of this Note, the Holder hereof does not intend to charge and the Company shall not be required to pay any interest or other fees or charges in excess of the maximum interest permitted by applicable law, and any payments in excess of such
maximum shall be refunded to the Company or credited to reduce principal hereunder. All payments received by the Holder hereunder will be applied first to costs of collection, if any, then to interest and the balance to principal. 

This Note is one of a series of Senior Subordinated Convertible Promissory Notes of like tenor (collectively, the
“Notes”) to be issued by the Company pursuant to the terms of that certain Fourth Amended and Restated Note Purchase Agreement dated as of October 1, 2010 (as may be amended and/or restated from time to time, the
“Purchase Agreement”) among the 

 
Company and the purchasers set forth on the Schedule I thereto (the “Schedule of Purchasers”). Capitalized terms not otherwise defined herein shall have the
respective meanings ascribed to such terms in the Purchase Agreement. By acceptance of this Note, the Holder and the Company each hereby agree that each of the Notes shall rank equally and ratably without priority over one another, and the Company
covenants and agrees that none of the Notes shall be paid, in whole or in part, unless a reasonably equivalent, pro rata payment is made with respect to all other Notes so as to maintain as near as possible the amount of the debt owing under the
Notes pro rata according to the respective balances owed as of the date immediately prior to such payment. This Note will be registered on the books of the Company or its agent as to principal and interest. Any transfer of this Note may be effected
only by surrender of this Note to the Company and reissuance of a new Note to the transferee. Payments of principal and interest will be made by wire transfer in immediately available United States funds transferred to the account of the Holder,
which account information shall have been furnished to the Company by the Holder for that purpose. 
 1. Subordination.
This Note is subordinate and junior in right of payment to the prior payment in full of all obligations of the Company under that certain Loan and Security Agreement between the Company and Hercules Technology Growth Capital, Inc.
(“Hercules”) dated March 20, 2007, all promissory notes issued by the Company to Hercules pursuant thereto and any other such obligations agreed to in the Fourth Amended and Restated Subordination Agreement among the
purchasers set forth on Schedule I to the Purchase Agreement, the Company and Hercules dated as of October 1, 2010. 
 2.
Maturity. The entire outstanding principal balance hereof, together with all accrued and unpaid interest thereon, shall be due and payable (i) automatically upon the occurrence of an Event of Default (as defined below) specified in
Section 6.1(c), 6.1(d), 6.1(e) or 6.1(f), or (ii) if occurring earlier than any Event of Default described in (i) above, upon demand made in writing by the Required Purchasers at any time upon the earlier of (a) December 31,
2011, unless such date is extended to a later date by an agreement in writing between the Company and the Required Purchasers (such original date or such later date, the “Maturity Date”), (b) a Sale of the Company (as
defined below) or (c) the occurrence of an Event of Default specified in Section 6.1(a) or 6.1(b). In order to extend the Maturity Date, the Required Purchasers and the Company shall agree in writing to extend the Maturity Date (an
“Extension Agreement”), and the Extension Agreement shall specify the date they elect to extend the Maturity Date. Following such Extension Agreement, every reference in the Note Purchase Agreement and the Notes
to the Maturity Date shall be deemed to refer to the Maturity Date set forth in the Extension Agreement. The Required Purchasers and Company may elect to extend the Maturity Date on successive occasions. 

3. Payment Upon Sale of the Company. 

(a) General. Upon the closing of a Sale of the Company occurring prior to the Maturity Date, the Holder shall be
entitled to receive an amount equal to the greater of: 
 (i) an amount equal to three times (3.0x) the
principal amount of this Note; or 
  

 2 

 (ii) the amount that the Holder would have received if the principal amount
of this Note plus any accrued unpaid interest thereon (the “Note Balance”), as of the closing date of the Sale of the Company, had been converted into shares of the Company’s Series B Preferred Participating Stock (as
defined in the Company’s Amended and Restated Certificate of Incorporation) immediately prior to the closing date of the Sale of the Company at a conversion price equal to the Applicable Conversion Price (as defined in the Charter) of the
Series B Preferred Participating Stock in effect at such time. 
 Immediately upon receipt by the Holder of payment pursuant to
Section 3(a)(i) or (ii), this Note shall no longer be deemed to be outstanding and all rights with respect to this Note shall immediately cease and terminate. 

(b) Sale of the Company. A “Sale of the Company” shall mean and include (i) a sale of
all or substantially all of the assets of the Company or all or fifty percent (50%) or more of the capital stock of the Company, or (ii) a merger, consolidation, sale, transfer or other transaction or series of related transactions
(excluding a financing transaction) in which the holders of the capital stock of the Company will hold, upon consummation of such transaction, less than fifty percent (50%) in interest of the voting securities of the surviving entity.

 4. Reserved 

5. Conversion upon Equity Sale. 

(a) Qualified Equity Sale. Immediately upon the closing of a Qualified Equity Sale (as defined below), the Note
Balance shall automatically be converted into fully paid and non-assessable shares of New Stock (as defined below). The type and class of capital stock of the Company to be issued to the Holder of this Note upon conversion pursuant to this
Section 5(a) (and the rights and privileges of the Holder thereof) shall be identical to the type and class of the capital stock issued by the Company in connection with the Qualified Equity Sale (the “New Stock”). Upon
conversion of this Note pursuant to this Section 5(a), subject to the provisions of Section 5(c) hereof, the holder of this Note shall be entitled to receive a number of shares of New Stock determined by dividing (A) the Note Balance
as of the Investor Conversion Date (as defined below) by: (B) (i) in the case of a Qualified Equity Sale that is not the initial public offering of the Company’s capital stock, an amount equal to eighty-five percent (85%) of the
price per share of New Stock paid by the investors in connection with the Qualified Equity Sale (the “New Stock Price”), or (ii) in the case of a Qualified Equity Sale that is the initial public offering of the
Company’s capital stock, an amount equal to eighty percent (80%) of the price to the public for the shares of the Company’s Common Stock (as defined herein) offered in the initial public offering (the “IPO New Stock
Price”). A “Qualified Equity Sale” shall mean and include the sale of shares of capital stock of the Company (other than a sale of shares of the Company’s Common Stock, $0.001 par value per share (the
“Common Stock”), or other securities to officers, directors or employees of, or consultants to, the Company in connection with their provision of services to the Company) in one transaction or series of related transactions,
which sale or sales, including without limitation any initial public offering, result in gross proceeds to the Company, not including any Note Balance converted to New Stock, of at least Ten Million Dollars ($10,000,000). 

 

 3 

 (b) Conversion upon Alternative Equity Sale. In the event that the
Company intends to consummate an Alternative Equity Sale (as defined below), the Company shall send written notice at least ten (10) business days prior to the closing of such Alternative Equity Sale to the Holder hereof (the
“Company Notice”), which Company Notice shall describe the Alternative Equity Sale in reasonable detail. Upon written notice to the Company delivered prior to the closing of such Alternative Equity Sale, the
Required Purchasers may elect to convert the Note Balance of all, but not less than all, of the Notes issued to all Purchasers under the Purchase Agreement then outstanding into fully paid and non-assessable shares of Alternative Stock (as defined
below); provided that if the Required Purchasers do not so elect, then the Holder hereof may, by written notice to the Company not more than five (5) business days following receipt by the Holder of the Company Notice, elect to convert all or
part of the Note Balance into fully paid and non-assessable shares of Alternative Stock. The type and class of capital stock of the Company to be issued to the holder of this Note upon conversion pursuant to this Section 5(b) (and the rights
and privileges of the holders thereof) shall be identical to the type and class of the capital stock issued by the Company in connection with the Alternative Equity Sale (the “Alternative Stock”). Upon
conversion of this Note pursuant to the provisions of this Section 5(b), subject to the provisions of Section 5(c) hereof, the Holder of this Note shall be entitled to receive a number of shares of Alternative Stock determined by dividing
(A) the Note Balance to be converted by (B) an amount equal to eighty five percent (85%) of the price per share of Alternative Stock paid by the purchasers of such equity securities in connection with the Alternative Equity Sale (the
“Alternative Stock Price”). “Alternative Equity Sale” shall mean and include any sale of shares of capital stock of the Company (other than a sale of shares of Common Stock or other
securities to officers, directors or employees of, or consultants to, the Company in connection with their provision of services to the Company) in one transaction or series of related transactions, which sale or sales result in gross proceeds to
the Company of less than Ten Million Dollars ($10,000,000). 
 (c) Fractional Shares. No fractional
shares of capital stock of the Company shall be issued upon conversion of this Note. In lieu of any fractional shares to which the holder would otherwise be entitled, the Company shall pay cash equal to such fraction multiplied by the New Stock
Price, IPO New Stock Price or the Alternative Stock Price, as applicable. 
 (d) Mechanics of Conversion;
Investor Sale. 
 (i) Upon the closing (the “Investor Conversion
Date”) of a Qualified Equity Sale or an Alternative Equity Sale if either (y) the Required Purchasers have elected to convert the Note Balance of all Notes then outstanding or (z) the Holder hereof has elected to
convert the Note Balance of this Note (each being referred to herein as an “Investor Sale”), this Note, or any portion hereof, as applicable, shall be converted automatically without any further action by the
holder and whether or not this Note is surrendered to the Company or the transfer agent for this Note, provided, however, that the Company shall not be obligated to issue a certificate or certificates evidencing the shares of New Stock or
Alternative Stock (each being referred to herein as “Investor Stock”) into which this Note is convertible unless this Note is delivered to the Company, or the holder notifies the Company that the Note has been
lost, stolen, or destroyed and executes and delivers an agreement satisfactory to the Company to indemnify the Company from any loss incurred by it in connection therewith and, if the Company so elects, provides an appropriate indemnity. 

 

 4 

 (ii) The Company shall cause notice of the Investor Sale to be mailed to the
registered holder of this Note, at such holder’s address appearing in the records of the Company, as promptly as practicable after the Investor Conversion Date. Thereafter, the holder shall surrender this Note at the place designated in such
notice, together with a written notice by the holder of this Note stating such holder’s name or the names of his, her or its nominees in which such holder wishes the certificate or certificates for shares of Investor Stock to be issued. If
required by the Company, the Note surrendered shall be endorsed or accompanied by a written instrument or instruments of surrender, in form satisfactory to the Company, duly executed by the registered holder or his or its attorney duly authorized in
writing. 
 (iii) Upon authorization of the sale of shares of its capital stock in an Investor Sale, for the
purpose of effecting the conversion of this Note as provided in Section 5(a) or 5(b) hereof, the Company shall have (A) authorized a sufficient number of shares of Investor Stock to effect the conversion of the Note Balance, or any portion
thereof, as applicable, (B) reserved such stock as to which the Holder would be entitled upon conversion of such Investor Stock and (C) taken all other actions reasonably requested by the Holder to effect the foregoing. The Company shall
take all such reasonable actions as may be necessary to assure that all Investor Stock which may be issuable upon the conversion of this Note and all shares of stock issuable upon conversion or exercise thereof may be issued without violation of any
applicable law or governmental regulation. 
 (iv) Immediately upon the Investor Conversion Date, this Note shall
be cancelled and no longer be deemed to be outstanding and all rights with respect to this Note shall immediately cease and terminate on the Investor Conversion Date, except only the right of the holder to receive the shares of Investor Stock to
which it is entitled as a result of the conversion on the Investor Conversion Date, together with any cash in lieu of fractional shares. Notwithstanding the foregoing, upon the Investor Conversion Date, the Company shall be released from all
obligations arising under this Note. 
 (v) The Company shall pay any and all issue and other taxes that may be
payable in respect of any issuance or delivery of shares of Investor Stock upon conversion of this Note pursuant to Section 5(a) or 5(b) hereof. The Company shall not, however, be required to pay any tax which may be payable in respect of any
transfer involved in the issuance and delivery of shares of Investor Stock in a name other than that of the registered holder of this Note, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance
has paid to the Company the amount of any such tax or has established, to the satisfaction of the Company, that such tax has been paid. 
  

 5 

 6. Default 

6.1 Events of Default. Notwithstanding any provision of this Note to the contrary, each of the following shall
constitute an event of default (each an “Event of Default”): 
 (a) the Company fails to
pay any amount of principal or interest due hereunder when due; 
 (b) the Company’s breach or violation of
any other covenant, agreement or condition under this Note or under the Purchase Agreement, which breach or violation is not cured within ten (10) days after written notice of such default from the Required Purchasers; 

(c) any of the Company’s indebtedness for borrowed money is accelerated as a result of a default or breach of or
under any agreement or instrument evidencing or relating to money borrowed from Hercules Technology Growth Capital, Inc. or its affiliates; 

(d) the Company admits in writing its inability to pay its debts as they become due, or makes a general assignment for the
benefit of creditors; 
 (e) the Company commences any case or other proceeding seeking reorganization,
arrangement, adjustment, liquidation, dissolution or composition of its company structure or its debts under any law relating to bankruptcy, insolvency, reorganization or relief of debtors, or seeking appointment of a receiver, trustee, custodian or
other similar official for it or for all or any part of its property, or shall take any action to authorize any of the foregoing; or 

(f) any case or proceeding is commenced against the Company to have an order for relief entered against it as debtor or
seeking reorganization, arrangement, adjustment, liquidation, dissolution or composition of its structure or its debts under any law relating to bankruptcy, insolvency, reorganization or relief of debtors, or seeking other similar official relief
for it or any part of its property, and such case or proceeding (x) results in the entry of an order for relief against it which is not fully stayed within five (5) business days after the entry thereof or (y) is not dismissed within
one hundred twenty (120) days of commencement. 
 6.2 Remedies Upon Event of Default. Upon any Event
of Default, the Required Purchasers may, by written notice to the Company, declare this Note to be due and payable, whereupon the outstanding principal and accrued interest under this Note shall be immediately due and payable; provided that, in the
case of an Event of Default pursuant to any of Sections 6.1(c), 6.1(d), 6.1(e) or 6.1(f), the outstanding principal and accrued interest under this Note shall become due and payable without notice or demand. 

7. New Note. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this
Note, the Company will issue a new promissory note, of like tenor and amount and dated the original date of this Note, in lieu of such lost, stolen, destroyed or mutilated Note, and in such event the Holder thereof agrees to indemnify and hold
harmless the Company in respect of any such lost, stolen, destroyed or mutilated Note. 
 8. Expenses of Collection. The
Company agrees to pay all of the Holder’s reasonable costs in collecting and enforcing this Note, including all attorney’s fees and disbursements, subject to any limitation imposed by law. 

 

 6 

 9. Notices. All notices, requests, consents and other communications hereunder shall
be in writing, shall be addressed to the receiving party’s address set forth below or to such other address as a party may designate by notice hereunder, and shall be delivered (a) by hand, (b) by telecopy or facsimile transmission,
(c) by a nationally recognized (or substantially equivalent international) overnight courier, or (d) by certified mail, return receipt requested, postage prepaid. 

 

			
	If to Holder:	  	To its address set forth on the Schedule of Purchasers;
		
	With a copy to:	  	 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One Financial Center
 Boston, MA 02111

Attn: Lewis Geffen, Esq.
 (617) 348-1834
(Telephone)
 (617) 542-2241 (Fax)

	  
		
	If to the Company:	  	 Aegerion Pharmaceuticals, Inc.

CenterPointe IV
 1140 Route 22 East, Suite 304

 Bridgewater, NJ 08807
 Attn: William
H. Lewis,
 President
 Telephone: (908)
704-1300
 Telecopier: (908) 541-1155

	  
	  
		
	With copies to:	  	 Goodwin Procter LLP

53 State Street
 Boston, MA 02109

Attn: Michael H. Bison, Esq.
 Telephone: (617)
570-1933
 Telecopier: (617) 523-1231

	  

 All notices, requests, consents and other communications hereunder shall be
deemed to have been given (a) if by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (b) if made by telecopy or facsimile transmission, at the time that receipt thereof has been
acknowledged by electronic confirmation or otherwise, (c) if sent by overnight courier, on the next business day (or if sent overseas, on the second business day) following the day such notice is delivered to the courier service, or (d) if
sent by registered or certified mail, on the 5th business day (or if sent overseas, on the 10th business day) following the day such mailing is made. 

10. Waiver by Company. The Company hereby expressly waives presentment, demand, and protest, notice of demand, dishonor and
nonpayment of this Note, and all other notices or demands of any kind in connection with the delivery, acceptance, performance, default or enforcement hereof, and hereby consents to any delays, extensions of time, renewals, waivers or modifications
that may be granted or consented to by the Holder hereof with respect to the time of payment or any other provision hereof. 
  

 7 

 11. Amendment and Waiver. Any term, covenant, agreement or condition of the Notes
may, with the written consent of the Company and Required Purchasers, be amended or compliance therewith may be waived (either generally or in a particular instance and either retroactively or prospectively), by one or more substantially concurrent
written instruments, provided that (a) without the consent of the holders of all of the Notes at the time outstanding no such amendment or waiver shall (i) decrease the principal amount due under or the rate of interest on any Note,
(ii) change the pro rata payment terms of the Notes or (iii) lower the percentage of holders of Notes required to approve any such amendment or effect any such waiver and (b) no such amendment or waiver shall extend to or affect any
obligation not expressly amended or waived or impair any right consequent thereto. Originals or true and correct copies of any amendment, waiver or consent effected pursuant to this Section 11 shall be delivered by the Company to each holder of
Note promptly (but in any event not later than five days) following the effective date thereof. 
 12. Delays or
Omissions. It is agreed that no delay or omission to exercise any right, power or remedy accruing to the Holder, upon any breach or default of the Company under this Note shall impair any such right, power or remedy, nor shall it be construed to
be a waiver of any such breach or default, or any acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default
theretofore or thereafter occurring. 
 13. Severability. In the event any one or more of the provisions of this Note
shall for any reason be held to be invalid, illegal or unenforceable, in whole or in part or in any respect, or in the event that any one or more of the provisions of this Note operate or would prospectively operate to invalidate this Note, then and
in any such event, such provision(s) only shall be deemed null and void and shall not affect any other provision of this Note and the remaining provisions of this Note shall remain operative and in full force and effect and in no way shall be
affected, prejudiced, or disturbed thereby. 
 14. Descriptive Headings. Section headings appearing in this Note have
been inserted for convenience of reference only and shall be given no substantive meaning or significance whatsoever in construing the terms and provisions of this Note. 

15. Governing Law. This Note shall be governed by and construed and enforced in accordance with the laws of the General
Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be construed in accordance with and governed by the internal laws of the State of New Jersey, without giving effect to the conflict of
law principals thereof. 
 [Remainder of Page Intentionally Left Blank] 

 

 8 

 IN WITNESS WHEREOF, the Company has signed this Note as an instrument under seal as of the
date written above. 
  

			
	AEGERION PHARMACEUTICALS, INC.
		
	By:	 	 
	Name:	 	Marc D. Beer
	Title:	 	Chief Executive Officer

  

 9Employment Agreement with William H. Lewis

 Exhibit 10.18 

EMPLOYMENT AGREEMENT 

This Employment Agreement (“Agreement”) is made as of the 5th day of October, 2010 (the “Effective Date”), between
Aegerion Pharmaceuticals, Inc. a Delaware corporation (the “Company”), and William H. Lewis, an individual who currently resides at 22 Canterbury Lane, Summit, NJ 07901, (the “Executive”) (together the “Parties”).

 WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and
conditions set forth herein. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 

1. Position and Duties. The Executive shall serve as the President of the Company. In such capacity, Executive shall have such
powers and duties and responsibilities as may from time to time be prescribed by the Company’s Chief Executive Officer and/or the Company’s Board of Directors (the “Board”). The Executive shall devote his full working time and
efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may manage his personal investments, engage in religious, charitable or other community activities, as long as such activities do not pose an actual or
apparent conflict of interest and do not interfere with the Executive’s performance of his duties to the Company. Executive represents that he has provided the Company with a comprehensive list of all outside professional activities with which
he is currently involved or reasonably expects to become involved. In the event that, during his employment by the Company, the Executive desires to engage in other outside professional activities, not included on such list, Executive will first
seek written approval from the Board and such approval shall not be unreasonably withheld. 
 2. Compensation and Related
Matters. 
 (a) Base Salary. The Executive’s initial base salary shall be paid at the rate of $300,000 per year.
The Executive’s base salary shall be reviewed annually by the Board or the Compensation Committee of the Board (the “Compensation Committee”). The base salary in effect at any given time is referred to herein as “Base
Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for senior executives. 

(b) Annual Bonus. The Executive shall be eligible to receive an annual cash bonus as determined by the Board or the Compensation
Committee (the “Bonus”). The Bonus shall be based on an annual target and the achievement of performance goals. The Executive’s target shall be 40 percent of his Base Salary. The Executive’s performance goals shall be established
by the Board or the Compensation Committee and the achievement of those goals shall be determined in the sole discretion of the Board or the Compensation Committee. Except as otherwise provided herein, to earn any part of the Bonus, the Executive
must be employed by the Company on December 31 of the applicable bonus year and such Bonus shall be paid to Executive on or before March 15 of the immediately following calendar year. 

 (c) Special Bonus. The Executive shall be eligible to receive a cash bonus equal to
10% of his Base Salary upon acceptance (the “Acceptance Date”) by the U.S. Food and Drug Administration (“FDA”) of a New Drug Application for lomitapide (the “Lomitapide NDA”). Any such bonus will not be earned unless
the Executive is employed by the Company on the Acceptance Date and shall be paid as soon as reasonably practicable following such Acceptance Date but, in any event, no later than March 15 of the immediately following calendar year. 

(d) Equity Grant. The Company shall award the Executive an option (the “Option Award”) to purchase 620,735 shares of the
Company’s common stock, $0.001 par value per share (the “Common Stock”). The Executive shall remain eligible to receive subsequent equity awards from time to time in accordance with the Company’s compensation policies and
procedures then in effect, in any such case, as determined by the Board (or Compensation Committee thereof) acting in its sole discretion. The Option Award shall have an exercise price equal to the fair market value of the Common Stock on the date
of grant (as determined by the Board or Compensation Committee thereof). Sixty percent of the Option Award shall vest in equal monthly installments over the four year period commencing as of the date of grant, 20 percent of the Option Award shall
vest in equal monthly installments over the four year period commencing on the Acceptance Date and the remaining 20 percent of the Option Award shall vest in full upon approval by the FDA of the Lomitapide NDA, subject to the terms and conditions
set forth in the Aegerion Pharmaceuticals, Inc. 2006 Stock Option and Grant Plan, as amended, and associated equity award agreements (collectively the “Equity Award Documents”). The term of the Option Award shall be ten (10) years
after the date the Option Award is granted. In connection with a termination of employment within 24 months following a Sale Event (as defined in the Equity Award Documents), 100 percent of Executive’s then outstanding unvested equity shall
vest and become fully exercisable or nonforfeitable as of the date of such termination. 
 (e) Expenses. The Executive
shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by him in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executive
officers. 
 (f) Other Benefits. The Executive shall be entitled to continue to participate in or receive benefits under
the Company’s employee benefit plans as may be adopted and amended from time to time, subject to the terms and conditions of those employee benefit plans. 

(g) Vacations. The Executive shall be entitled to accrue up to 25 days of paid vacation days in each year, which shall be accrued
ratably, and subject to the Company’s vacation policy in effect, and as may be amended from time to time. 
 3.
Termination. The Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances: 

(a) Death. The Executive’s employment hereunder shall terminate upon his death. 

 

 2 

 (b) Disability. The Company may terminate the Executive’s employment if the
Executive incurs a disability and is unable to perform the essential functions of the Executive’s position with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question
shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position or positions with or without reasonable accommodation, the Executive may, and
at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive’s guardian has no reasonable objection as to whether the Executive is
so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection
with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company’s determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed
to waive the Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et
seq. 
 (c) Termination by Company for Cause. The Company may terminate the Executive’s employment at any time
for Cause. For purposes of this Agreement, “Cause” shall mean any of the following by Executive: (i) dishonesty, embezzlement, misappropriation of assets or property of the Company; (ii) gross negligence, willful misconduct,
theft, fraud, or breach of fiduciary duty to the Company; (iii) violation of federal or state securities laws; or (iv) the conviction of a felony, or any crime involving moral turpitude, including a plea of guilty or nolo contendere;
(v) a material breach of any material provision of this Agreement; or (vi) a material breach of any of the Company’s written policies relating to conduct or ethics. Notwithstanding the foregoing, the Executive’s employment
shall not be terminated by the Company for Cause unless the Executive is first provided with written notice of termination and, if the act or omission that is the basis of the Cause determination (the “Cause Event”) is curable and has not
resulted in injury or potential injury to the Company, the Executive is first provided with a fifteen day opportunity to cure the Cause Event. 

(d) Termination by the Company Without Cause. The Company may terminate the Executive’s employment at any time without Cause.
Any termination by the Company of the Executive’s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under
Section 3(a) or 3(b) shall be deemed a termination without Cause. 
 (e) Termination by the Executive. The
Executive may terminate his employment hereunder at any time for any reason, including but not limited to Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has complied with the “Good Reason
Process” (hereinafter defined) following the occurrence of any of the following events: (i) a material diminution in the Executive’s responsibilities, authority or duties; (ii) a material diminution in the Executive’s Base
Salary; (iii) a material change without the Executive’s consent of the principal location of the Executive’s offices provided that such consent may not be unreasonably withheld, or (iv) the material breach of a material provision
of this Agreement by the Company. “Good Reason Process” shall mean that (i) the Executive 
  

 3 

 
reasonably determines in good faith that a “Good Reason” condition has occurred; (ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason
condition within 30 days of the first occurrence of such condition; (iii) the Executive cooperates in good faith with the Company’s efforts, for a period not less than 30 days following such notice (the “Cure Period”), to remedy
the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) the Executive terminates his employment within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition
during the Cure Period, Good Reason shall be deemed not to have occurred. 
 (f) Notice of Termination. Except for
termination as specified in Section 3(a), any termination of the Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of
this Agreement, a “Notice of Termination” shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon. 

(g) Date of Termination. “Date of Termination” shall mean: (i) if the Executive’s employment is terminated by
his death, the date of his death; (ii) if the Executive’s employment is terminated on account of disability under Section 3(b) or by the Company with Cause under Section 3(c) or without Cause under Section 3(d) on the date
the Notice of Termination is given; (iii) if the Executive’s employment is terminated by the Executive under Section 3(e) without Good Reason, 30 days after the date on which a Notice of Termination is given, and (iv) if the
Executive’s employment is terminated by the Executive under Section 3(e) with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Executive
gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement. 

4. Compensation Upon Termination. 

(a) Termination Generally. If the Executive’s employment with the Company is terminated for any reason, the Company shall pay
or provide to the Executive (or to his authorized representative or estate) any earned but unpaid salary and bonus, if any, unpaid expense reimbursements, accrued but unused vacation and any vested benefits the Executive may have under any employee
benefit plan of the Company (the “Accrued Benefit”) on or before the time required by law but in no event more than 30 days after the Executive’s Date of Termination. 

(b) Termination by the Company Without Cause or by the Executive with Good Reason or Termination Upon Death or Disability. If the
Executive’s employment is terminated by the Company without Cause as provided in Section 3(d), the Executive terminates his employment for Good Reason as provided in Section 3(d), or the Executive’s employment is terminated on
account of death or disability as provided in Sections 3(a) and 3(b), then the Company shall, through the Date of Termination, pay the Executive (or to his authorized representative or estate) his Accrued Benefit. In addition, subject to the
Executive providing the Company with a fully effective separation agreement that includes a general release of claims in a form and manner reasonably satisfactory to the Company (the “Release”) within the 35-day

  

 4 

 
period following the Date of Termination (it being understood that such separation agreement and Release will not be required in the case of Executive’s death), Executive (or his authorized
representative or estate) shall be entitled to the following payments and benefits (collectively the “Severance Benefits”): 

(i) the Company shall pay the Executive severance pay in the form of continuation of Executive’s Base Salary for
twelve (12) months in accordance with the Company’s payroll practice, beginning on the Company’s first regular payroll date that occurs 35 days after the Date of Termination. Solely for purposes of Section 409A of the
Internal Revenue Code of 1986, as amended (the “Code”), each salary continuation payment is considered a separate payment; 

(ii) subject to the Executive’s timely election of COBRA and copayment of premium amounts at the active
employees’ rate, the Executive may continue to participate in the Company’s group health and dental program until the earlier of (i) twelve (12) months from the Date of Termination, and (ii) the date the Executive becomes
re-employed with benefits substantially comparable to the benefits provided under the corresponding Company plan; 

(iii) notwithstanding anything to the contrary in any Equity Award Documents, in the event that the Executive’s
employment is terminated by the Company without Cause or by the Executive with Good Reason and the Date of Termination occurs within twelve (12) months of the Effective Date (a) 25% of the Executive’s then outstanding unvested equity
awards shall vest and become fully exercisable or nonforfeitable as of the Date of Termination, and (b) Executive shall have ninety (90) days from the Date of Termination to exercise vested equity awards; and 

(iv) in the event that the Executive’s employment is terminated by the Company without Cause or by the Executive with
Good Reason and the Date of Termination occurs within twenty four (24) months following Sale Event (as defined in the Equity Award Documents), the Bonus payment the Executive earned pursuant to Section 2(b) of this Agreement for the bonus
period that immediately preceded the Date of Termination. 
 Notwithstanding anything herein to the contrary, in the case of a termination due
to death or disability, the Executive shall only be entitled to the Severance Benefits set forth in Sections 4(b)(i) and 4(b)(ii), and such Severance Benefits will continue for a period of six (6) months instead of twelve (12) months.
Notwithstanding the foregoing, the Severance Benefit set forth in Section 4(b)(i) shall be reduced dollar for dollar by any compensation Executive receives from another employer during the period between the Date of Termination and the last day
of the severance period (the “Severance Benefits Period”) if the Executive becomes re-employed during the Severance Benefits Period. The Executive agrees to give prompt notice of any employment during the Severance Benefits Period and
shall respond promptly to any reasonable inquiries concerning his professional activities. If the Company makes any overpayments of Severance Benefits, Executive shall promptly return any such overpayments to the Company and/or hereby authorizes
deductions from future Severance Benefit amounts. The foregoing shall not create any obligation on the part of the Executive to seek re-employment after the Date of Termination. 

 

 5 

 5. Section 409A. 

(a) Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the
meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive
becomes entitled to under this Agreement on account of the Executive’s separation from service would be considered deferred compensation subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result
of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive’s separation
from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the
six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. 

(b) All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or
incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following
the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any
other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. 

(c) To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation”
under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such payments or benefits shall be payable only upon the Executive’s “separation from
service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h). 

(d) The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any
provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. The parties agree that this
Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder
without additional cost to either party. 
  

 6 

 (e) The Company makes no representation or warranty and shall have no liability to the
Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. 

6. Confidential Information, Noncompetition and Cooperation; Nondisparagement. 

(a) Restrictive Covenant. As a condition of Executive’s employment and as a material term of this Agreement, the Executive
agrees to comply with the Employee Confidentiality, Assignment and Noncompetition Agreement attached hereto as Exhibit 1, the terms of which are hereby incorporated by reference into Section 6 of this Agreement. 

(b) Litigation and Regulatory Cooperation. During and after the Executive’s employment, the Executive shall cooperate fully
with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed
by the Company, provided, that the Executive will not have an obligation under this paragraph with respect to any Claim in which the Executive has filed directly against the Company or related persons or entities. The Executive’s full
cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During
and after the Executive’s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to
events or occurrences that transpired while the Executive was employed by the Company, provided the Executive will not have any obligation under this paragraph with respect to any claim in which the Executive has filed directly against the Company
or related persons or entities. The Company shall reimburse the Executive for any reasonable out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this Section 6(b). 

(c) Injunction; Termination of Post-employment Payments. The Executive agrees that it would be difficult to measure any damages
caused to the Company which might result from any breach by the Executive of the promises set forth in this Section 6, including without limitation, any provision of Exhibit 1, and that in any event money damages would be an inadequate remedy
for any such breach. Accordingly, the Executive agrees that if the Executive breaches, or proposes to breach, any portion of this Agreement, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other
appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company. In addition to the foregoing, if the Executive breaches any of the provisions contained in Section 6 of this Agreement, the
Company shall, in addition to all other rights and remedies, have the right to cease paying any payments or benefits pursuant to Section 4(b)) of this Agreement. Any such termination of payment or benefits shall have no effect on the Release or
any of Executive’s post-employment obligations to the Company. 
 7. Indemnification. The Company and the Executive
shall enter into an indemnification agreement in a form approved by the Board for the Company’s senior executives. 
  

 7 

 8. Consent to Jurisdiction. To the extent that any court action is initiated to
enforce this Agreement, the parties hereby consent to the jurisdiction of the state and federal courts of the Commonwealth of Massachusetts. Accordingly, with respect to any such court action, the Executive (a) submits to the personal
jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process. 

9. Integration. This Agreement, along with Exhibit 1, the Equity Award Documents and any other option agreements between the
Company and the Executive, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter herein. 

10. Withholding. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts
required to be withheld by the Company under applicable law. Nothing herein shall be construed to obligate the Company to design or implement any compensation arrangement in a way that minimizes tax consequences for Executive. 

11. Successor to the Executive. This Agreement shall inure to the benefit of and be enforceable by the Executive’s personal
representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Executive’s death after his termination of employment but prior to the completion by the Company of all payments due him under this
Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to his death (or to his estate, if the Executive fails to make such designation). 

12. Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any
section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to
which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. 

13. Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the
Executive’s employment to the extent necessary to effectuate the terms contained herein. 
 14. Waiver. No waiver of
any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this
Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. 

15. Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in
writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with
the Company or, in the case of the Company, at its main offices, attention of the Board. 
  

 8 

 16. Amendment. This Agreement may be amended or modified only by a written instrument
signed by the Executive and by a duly authorized representative of the Company. 
 17. Governing Law. This is a
Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts without giving effect to the conflict of laws principles of such state. With respect to any disputes concerning
federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit. 

18. Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall
be taken to be an original; but such counterparts shall together constitute one and the same document. 
 19. Successor to
Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this
Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material
breach of this Agreement. 
 20. Gender Neutral. Wherever used herein, a pronoun in the masculine gender shall be
considered as including the feminine gender unless the context clearly indicates otherwise. 
 IN WITNESS WHEREOF, the parties
have executed this Agreement effective on the date and year first above written. 
  

			
	AEGERION PHARMACEUTICALS, INC.
		
	 By:
	 	 /s/ Marc D. Beer

	 Its:
	 	 Chief Executive Officer

	
	EXECUTIVE
	
	 /s/ William H. Lewis

	William H. Lewis
	
	 October 5, 2010

	Date

  

 9 

 Exhibit 1 

AEGERION PHARMACEUTICALS, INC. 

Employee Confidentiality, Assignment and Noncompetition Agreement 

In consideration and as a condition of my employment or continued employment by Aegerion Pharmaceuticals, Inc. (the “Company”),
I agree as follows: 
 1. Proprietary Information. I agree that all information, whether or not in writing,
concerning the Company’s business, technology, business relationships or financial affairs which the Company has not released to the general public (collectively, “Proprietary Information”) is and will be the exclusive property of the
Company. By way of illustration, Proprietary Information may include information or material which has not been made generally available to the public, such as: (a) corporate information, including plans, strategies, methods, policies,
resolutions, negotiations or litigation; (b) marketing information, including strategies, methods, customer identities or other information about customers, prospect identities or other information about prospects, or market analyses or
projections; (c) financial information, including cost and performance data, debt arrangements, equity structure, investors and holdings, purchasing and sales data and price lists; and (d) operational and technological
information, including plans, specifications, manuals, forms, templates, software, designs, methods, procedures, formulas, discoveries, inventions, improvements, concepts and ideas; and (e) personnel information, including personnel
lists, reporting or organizational structure, resumes, personnel data, compensation structure, performance evaluations and termination arrangements or documents. Proprietary Information also includes information received in confidence by the Company
from its customers or suppliers or other third parties. 
 2. Recognition of Company’s Rights. I will not, at
any time, without the Company’s prior written permission, either during or after my employment, disclose any Proprietary Information to anyone outside of the Company, or use or permit to be used any Proprietary Information for any purpose other
than the performance of my duties as an employee of the Company. I will cooperate with the Company and use my best efforts to prevent the unauthorized disclosure of all Proprietary Information. I will deliver to the Company all copies of Proprietary
Information in my possession or control upon the earlier of a request by the Company or termination of my employment. 
 3.
Rights of Others. I understand that the Company is now and may hereafter be subject to non-disclosure or confidentiality agreements with third persons which require the Company to protect or refrain from use of proprietary information.
I agree to be bound by the terms of such agreements in the event I have access to such proprietary information. 
 4.
Commitment to Company; Avoidance of Conflict of Interest. While an employee of the Company, I will devote my full-time efforts to the Company’s business and I will not engage in any other business activity that conflicts with my
duties to the Company. I will advise the Chief Executive Officer of the Company at such time as any activity of either the Company or another business presents me with a conflict of interest or the appearance of a conflict of interest as an employee
of the Company. I will take whatever action is requested of me by the Company to resolve any conflict or appearance of conflict which it finds to exist. 

5. Developments. I will make full and prompt disclosure to the Company of all inventions, discoveries, designs,
developments, methods, modifications, improvements, processes, algorithms, databases, computer programs, formulae, techniques, trade secrets, graphics or images, and audio or visual works and other works of authorship, whether or not patentable or
copyrightable, that are created, made, conceived or reduced to practice by me (alone or jointly with others) or under my direction during the period of my employment (collectively, the “Developments”). I acknowledge that all work performed
by me is on a “work for hire” basis, and I hereby do assign and transfer and, to the extent any such assignment cannot be made at present, will assign and transfer, to the Company and its successors and assigns all my right, title and
interest in all Developments that (a) relate to the business of the Company or any customer of the Company or any of the products or services being researched, developed, manufactured or sold by the Company or which may be used with such
products or services; or (b) result from tasks assigned to me by the Company; or (c) result from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by the Company
(“Company-Related Developments”), and all related patents, patent applications, trademarks and trademark applications, copyrights and copyright applications, and other intellectual property rights in all countries and territories worldwide
and under any international conventions (“Intellectual Property Rights”). 
 To preclude any possible uncertainty, I have set forth on
Exhibit A attached hereto a complete list of Developments that I have, alone or jointly with others, conceived, developed or reduced to practice prior to the commencement of my employment with the Company that I consider to be my property or
the property of third parties and that I wish to have excluded from the scope of this Agreement (“Prior Inventions”). If disclosure of any such Prior Invention would cause me to violate any prior confidentiality agreement, I understand
that I am not to list such Prior Inventions in Exhibit A but am only to disclose a cursory name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such inventions has not been made
for that reason. I have also listed on Exhibit A all patents and patent applications in which I am named as an inventor, other than those which have been assigned to the Company (“Other Patent Rights”). If no such disclosure is

 
attached, I represent that there are no Prior Inventions or Other Patent Rights. If, in the course of my employment with the Company, I incorporate a Prior Invention into a Company product,
process or machine or other work done for the Company, I hereby grant to the Company a nonexclusive, royalty-free, paid-up, irrevocable, worldwide license (with the full right to sublicense) to make, have made, modify, use, sell, offer for sale and
import such Prior Invention. Notwithstanding the foregoing, I will not incorporate, or permit to be incorporated, Prior Inventions in any Company-Related Development without the Company’s prior written consent. 

This Agreement does not obligate me to assign to the Company any Development which, in the sole judgment of the Company, reasonably exercised, is
developed entirely on my own time and does not relate to the business efforts or research and development efforts in which, during the period of my employment, the Company actually is engaged or reasonably would be engaged, and does not result from
the use of premises or equipment owned or leased by the Company. However, I will also promptly disclose to the Company any such Developments for the purpose of determining whether they qualify for such exclusion. I understand that to the extent this
Agreement is required to be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this paragraph 5 will be interpreted not to apply to
any invention which a court rules and/or the Company agrees falls within such classes. I also hereby waive all claims to any moral rights or other special rights which I may have or accrue in any Company-Related Developments. 

6. Documents and Other Materials. I will keep and maintain adequate and current records of all Proprietary Information and
Company-Related Developments developed by me during my employment, which records will be available to and remain the sole property of the Company at all times. 

All files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification
sheets, or other written, photographic or other tangible material containing Proprietary Information, whether created by me or others, which come into my custody or possession, are the exclusive property of the Company to be used by me only in the
performance of my duties for the Company. Any property situated on the Company’s premises and owned by the Company, including without limitation computers, disks and other storage media, filing cabinets or other work areas, is subject to
inspection by the Company at any time with or without notice. In the event of the termination of my employment for any reason, I will deliver to the Company all files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks,
layouts, charts, quotations and proposals, specification sheets, or other written, photographic or other tangible material containing Proprietary Information, and other materials of any nature pertaining to the Proprietary Information of the Company
and to my work, and will not take or keep in my possession any of the foregoing or any copies. 
 7. Enforcement of
Intellectual Property Rights. I will cooperate fully with the Company, both during and after my employment with the Company, with respect to the procurement, maintenance and enforcement of Intellectual Property Rights in Company-Related
Developments. I will sign, both during and after the term of this Agreement, all papers, including without limitation copyright applications, patent applications, declarations, oaths, assignments of priority rights, and powers of attorney, which the
Company may deem necessary or desirable in order to protect its rights and interests in any Company-Related Development. If the Company is unable, after reasonable effort, to secure my signature on any such papers, I hereby irrevocably designate and
appoint each officer of the Company as my agent and attorney-in-fact to execute any such papers on my behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any
Company-Related Development. 
 8. Non-Competition and Non-Solicitation. In order to protect the Company’s
Proprietary Information and good will, during my employment and for a period of twelve (12) months following the termination of my employment for any reason (the “Restricted Period”), I will not directly or indirectly, whether as
owner, partner, shareholder, director, manager, consultant, agent, employee, co-venturer or otherwise, engage, participate or invest in any business activity anywhere in the world that develops, manufactures or markets any products, or performs any
services, that are competitive with the products or services of the Company, or products or services that the Company or its affiliates, has under development or that are the subject of active planning at any time during my employment; provided that
this shall not prohibit any possible investment in publicly traded stock of a company representing less than one percent of the stock of such company. In addition, during the Restricted Period, I will not, directly or indirectly, in any manner,
other than for the benefit of the Company, (a) call upon, solicit, divert, take away, accept or conduct any business from or with any of the customers or prospective customers of the Company or any of its suppliers, and/or (b) solicit,
entice, attempt to persuade any other employee or consultant of the Company to leave the Company for any reason. I acknowledge and agree that if I violate any of the provisions of this paragraph 8, the running of the Restricted Period will be
extended by the time during which I engage in such violation(s). 
 9. Government Contracts. I acknowledge that
the Company may have from time to time agreements with other persons or with the United States Government or its agencies which impose obligations or restrictions on the Company regarding inventions made during the course of work under such
agreements or regarding the confidential nature of such work. I agree to comply with any such obligations or restrictions upon the direction of the Company. In addition to the rights assigned under paragraph 5, I also assign to the Company (or any
of its nominees) all rights which I have or acquired in any Developments, full title to which is required to be in the United States under any contract between the Company and the United States or any of its agencies. 

 

 2 

 10. Prior Agreements. I hereby represent that, except as I have fully
disclosed previously in writing to the Company, I am not bound by the terms of any agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of
my employment with the Company or to refrain from competing, directly or indirectly, with the business of such previous employer or any other party. I further represent that my performance of all the terms of this Agreement as an employee of the
Company does not and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by me in confidence or in trust prior to my employment with the Company. I will not disclose to the Company or induce the
Company to use any confidential or proprietary information or material belonging to any previous employer or others. 
 11.
Remedies Upon Breach. I understand that the restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and I consider them to be reasonable for such purpose. Any breach of this
Agreement is likely to cause the Company substantial and irrevocable damage and therefore, in the event of such breach, the Company, in addition to such other remedies which may be available, will be entitled to seek specific performance and other
injunctive relief, without the posting of a bond. If I violate this Agreement, in addition to all other remedies available to the Company at law, in equity, and under contract, I agree that I am obligated to pay all the Company’s costs of
enforcement of this Agreement, including attorneys’ fees and expenses. 
 12. Use of Voice, Image and Likeness.
During the period of my employment, I give the Company permission to use any and all of my voice, image and likeness, with or without using my name, in connection with the products and/or services of the Company, for the purposes of advertising
and promoting such products and/or services and/or the Company, and/or for other purposes deemed appropriate by the Company in its reasonable discretion, except to the extent expressly prohibited by law. 

13. Publications and Public Statements. I will obtain the Company’s written approval before publishing or submitting
for publication any material that relates to my work at the Company and/or incorporates any Proprietary Information. 
 14.
No Employment Obligation. I understand that this Agreement does not create an obligation on the Company or any other person to continue my employment. I acknowledge that, unless otherwise agreed in a formal written employment agreement
signed on behalf of the Company by an authorized officer, my employment with the Company is at will and therefore may be terminated by the Company or me at any time and for any reason, with or without cause. 

15. Survival and Assignment by the Company. I understand that my obligations under this Agreement will continue in
accordance with its express terms regardless of any changes in my title, position, duties, salary, compensation or benefits or other terms and conditions of employment. I further understand that my obligations under this Agreement will continue
following the termination of my employment regardless of the manner of such termination and will be binding upon my heirs, executors and administrators. The Company will have the right to assign this Agreement to its affiliates, successors and
assigns. I expressly consent to be bound by the provisions of this Agreement for the benefit of the Company or any parent, subsidiary or affiliate to whose employ I may be transferred without the necessity that this Agreement be resigned at the time
of such transfer. 
 16. Updating Information to the Company; Disclosure to Future Employers. For twelve
(12) months following termination of my employment, I will (i) notify the Company of any change in my address and of each subsequent employment or business activity, including the name and address of my employer or other post-Company
employment plans and the nature of my activities, and (ii) provide a copy of this Agreement to any prospective employer, partner or coventurer prior to entering into an employment, partnership or other business relationship with such person or
entity. 
 17. Severability. In case any provisions (or portions thereof) contained in this Agreement shall, for
any reason, be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or
unenforceable provision had never been contained herein. If, moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it
shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear. 

18. Interpretation. This Agreement will be deemed to be made and entered into in the Commonwealth of Massachusetts, and
will in all respects be interpreted, enforced and governed under the laws of the Commonwealth of Massachusetts. I hereby agree to consent to personal jurisdiction of the state and federal courts situated within Suffolk County, Massachusetts for
purposes of enforcing this Agreement, and waive any objection that I might have to personal jurisdiction or venue in those courts. 
  

 3 

 I UNDERSTAND THAT THIS AGREEMENT AFFECTS IMPORTANT RIGHTS. BY SIGNING BELOW, I CERTIFY THAT I HAVE READ
IT CAREFULLY AND AM SATISFIED THAT I UNDERSTAND IT COMPLETELY. 
 IN WITNESS WHEREOF, the undersigned has executed this
agreement as a sealed instrument as of the date set forth below. 
  

					
	 Signed:
	 	 /s/ William H. Lewis

		 	    (Employee’s full name)	 	
		
	 Type or print name: William H. Lewis
	 	

					
			
	 Date:
	 	 10/5/10
	 	

 EXHIBIT A 

 

			
	 To:
	 	Aegerion Pharmaceuticals, Inc. ,
		
	 From:
	 	  

		
	 Date:
	 	  

	
	 SUBJECT:             Prior
Inventions

 The following is a complete list of all inventions or improvements relevant to the subject
matter of my employment by the Company that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by the Company: 

 

					
		 	No inventions or improvements	 	
			
		 	See below:	 	
			
		 	  
	 	
			
		 	  
	 	
			
		 	  
	 	
			
		 	Additional sheets attached	 	
	
	 The following is a list of all patents and patent applications in which I have been named as an inventor:

			
		 	None	 	
			
		 	See below:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}]]